A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer

Inclusion Criteria: * Signed informed consent prior to any study specific procedures being performed * 18 - 80 years of age, inclusive * Assigned to Active Surveillance * Histologically confirmed, localized prostate cancer within 24 months of Screening * Gleason score 3+3 or 3+4 with one or more of the following characteristics: PSA \> 6.0 μg/L (ng/mL) and PSA density \> 0.15; PSA \> 10.0 μg/L and \< 20 μg/L (ng/mL); Any systematic core \> 50% involvement; Any PI-RADS score 4 or 5 on MRI; Any Gleason grade 4, Men of African descent * Patient has a negative bone scan within the last 12 months * Patient is able to have an MRI * Prostate volume ≤ 80 mL (measured by MRI within 12 months of Screening or has been scheduled for an MRI prior to Screening) * eGFR ≥ 30 mL/min, using the Cockcroft - Gault Equation: = \[{(140 - age in years) x (weight in kg)} x 1.23\] / serum Creatinine in micromol/l * AST, ALT and ALP ≤ 1.5 times upper limit of normal * Patient must be willing to comply with all study procedures * Patients must agree to the use of medically acceptable methods of contraception, including non-hormonal intrauterine device (IUD) or double barrier method (condom with foam or vaginal spermicidal suppository, diaphragm with spermicide) for the duration of the study (24 weeks), unless the patient and/or their partner has been surgically sterilized Exclusion Criteria: * PSA \> 20 μg/L (ng/mL) * Previous or ongoing hormonal therapy for prostate cancer * Positive urine culture before treatment with prophylactic antibiotics * Ongoing or previous therapy with finasteride or dutasteride in the last 3 months * Ongoing or previous invasive therapy for benign prostate hyperplasia (BPH) (e.g. TURP,TUMT, HIFU, etc.) * Use of pacemaker or other implanted electronic devices * Metal implant in the pelvis (e.g. hip replacement) that may affect the MRI of the prostate * Allergy to Liproca® Depot and its ingredients * Severe micturition symptoms (I-PSS \>15 or residual urine volume \> 150 mL) confirmed by repeat measurement or Qmax\< 12 mL/s * Ongoing therapy with the anticoagulant Acetyl Salicylic Acid (ASA) (more than 100mg/day) as preventive anti-thrombotic therapy should be withdrawn temporarily before treatment with Liproca® Depot, as determined by the Investigator. Other anticoagulants should be withdrawn in cooperation with the treating physician * Use of any previous focal prostate cancer treatment, such as transurethral resection, cryotherapy, high intensity frequency ultrasound (HIFU) and/or photodynamic therapy * Concomitant systemic treatment with corticosteroids or immune modulating agents * Known immunosuppressive disease (e.g. HIV, Type II Diabetes). Patients with well controlled Type II Diabetes may be included, as determined by Investigator * Simultaneous participation in any other study involving an investigational product or device,or having participated in a prostate cancer study within the last 12 months prior to starting treatment with Liproca® Depot * Infection in WHO Risk Group 2, 3 or 4